Home Cart Sign in  
Chemical Structure| 77191-36-7 Chemical Structure| 77191-36-7

Structure of Nefiracetam
CAS No.: 77191-36-7

Chemical Structure| 77191-36-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nefiracetam is a neuronal systems enhancer for Ro 5-4864-induced convulsions. Nefiracetam has GABAergic, cholinergic, and monoaminergic properties.

Synonyms: DZL-221; DM9384

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Nefiracetam

CAS No. :77191-36-7
Formula : C14H18N2O2
M.W : 246.30
SMILES Code : O=C(NC1=C(C)C=CC=C1C)CN2C(CCC2)=O
Synonyms :
DZL-221; DM9384
MDL No. :MFCD00209882
InChI Key :NGHTXZCKLWZPGK-UHFFFAOYSA-N
Pubchem ID :71157

Safety of Nefiracetam

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

Description
Nefiracetam enhances neuronal systems related to GABAergic, cholinergic, and monoaminergic pathways and is used to manage Ro 5-4864-induced convulsions. It targets the GABA Receptor. At submicromolar concentrations (0.01-0.1 μM), Nefiracetam leads to a short-term reduction of ACh-evoked currents, decreasing them to 30% and 38% of the baseline after a 10-minute exposure, respectively. At higher micromolar concentrations (1-10 μM), it causes a long-term enhancement of these currents. This interaction with PKA and PKC pathways might explain the cellular mechanisms underlying the cognitive enhancement provided by Nefiracetam[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00001933 Alzheimer's Disease PHASE2 COMPLETED 2025-01-02 National Institute of Neurolog... More >>ical Disorders and Stroke (NINDS), Bethesda, Maryland, 20892, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.06mL

0.81mL

0.41mL

20.30mL

4.06mL

2.03mL

40.60mL

8.12mL

4.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories